This first insights into the underlying biological determinant of cognitive impairment and QoL functional outcomes in CP point to the potential implications of targeting a single molecule, IGF-1, as a tailored prevention and treatment strategy to maintain cognitive and physical functioning in adults with CP, along with the possibility of preventing premature secondary health conditions and cumulative impairments. This evidence concerns the gene IGF1 and Cognitive impairment.